Angiostatic Treatment of Neuroblastoma: Minireview based on a doctoral thesis

Upsala Journal of Medical Sciences

Volumn 104, Issue 1, 1999, Pages 1-24

  Wassberg, Erik ^a,b  

^a UPPSALA UNIVERSITY   (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

Author keywords

Angiogenesis; Angiostatic treatment; Apoptosis; Differentiation; Neuroblastoma

Indexed keywords

ANIMAL; CHILD; HUMAN; NEOVASCULARIZATION (PATHOLOGY); NEUROBLASTOMA; PATHOLOGY; REVIEW;

ANIMALS; CHILD; HUMANS; NEOVASCULARIZATION, PATHOLOGIC; NEUROBLASTOMA;

EID: 0042731370     PISSN: 03009734     EISSN: None     Source Type: Journal    
DOI: 10.3109/03009739909178953     Document Type: Article

References (88)

1. Folkman J. Tumor angiogenesis: Therapeutic implications. N Engl J Med 1971; 285:1182-1186.
2. Folkman J. Tumor angiogenesis. In Mendelsohn J, Howley PM, Israel MA, Liotta LA (eds) The molecular basis of cancer. WB Saunders Co, Philadelphia, 1995, pp 206-232.
3. Schweigerer L. Antiangiogenesis as a novel therapeutic concept in pediatric oncology. J Mol Med 1995; 73:497-508.
4. Folkman J. Clinical applications of research on angiogenesis. N Engl J Med 1995; 333:1757-1763.
5. Gasparini G, Harris AL. Clinical importance of the determination of tumor angiogenesis in breast carcinoma: Much more than a new prognostic tool. J Clin Oncol 1995; 13:765-782.
6. Fox SB, Gatter KC, Harris AL. Tumor angiogenesis. J Pathol 1996; 179:232-237.
7. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996; 86:353-364.
8. Folkman J. New perspectives in clinical oncology from angiogenesis research. Eur J Cancer 1996; 32A:2534-2539.
9. Wassberg E, Christofferson R. Angiostatic treatment of neuroblastoma. Eur J Cancer 1997; 33:2020-2023.
10. Folkman J. Antiangiogenic therapy. In DeVita Jr VT, Hellman S, Rosenberg SA (eds) Cancer: Principles & practice of oncology (fifth edition). Lippincott-Raven Publishers, Philadelphia, 1997, pp 3075-3085.
11. D'Amore PA, Shima DT. Tumor angiogenesis: a physiological process or genetically determined? Cancer Metastasis Rev 1996; 15:205-212.
12. Shweiki D, Itin A, Soffer D, Keshet E. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 1992; 359:843-845.
13. Berthold F. Biology of neuroblastoma. In Pochedly C (ed) Neuroblastoma: Tumor Biology and Therapy. CRC Press, Boca Raton, 1990, pp 1-27.
14. Brodeur GM, Castleberry RP. Neuroblastoma. In Pizzo PA, Poplack DG (eds) Principles and practice of pediatric oncology. JB Lippincott Company, Philadelphia , 1993, pp 739-767.
15. Brodeur GM, Maris JM, Yamashiro DJ, Hogarty MD, White PS. Biology and genetics of human neuroblastomas. J Pediatr Hematol Oncol 1997; 19:93-101.
16. Auerbach W, Auerbach R. Angiogenesis inhibition: a review. Pharmacol Therap 1994; 63:265-311.
17. Chen C, Parengi S, Tolentino MJ, Folkman J. A strategy to discover circulating angiogenesis inhibitors generated by human tumors. Cancer Res 1995; 55:4230-4233.
18. O'Reilly MS, Holmgren L, Shing Y, Chen C, Rosenthal RA, Moses M, Lane WS, Cao Y, Sage EH, Folkman J. Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 1994; 79:315-328.
19. O'Reilly MS, Boehm T, Shing Y, Fukai N, Vasios G, Lane WS, Flynn E, Birkhead JR, Olsen BR, Folkman J. Endostatin: An endogenous inhibitor of angiogenesis and tumor growth. Cell 1997; 88:277-285.
20. O'Reilly MS, Holmgren L, Chen C, Folkman J. Angiostatin induces and sustains dormancy of human primary tumors in mice. Nat Med 1996; 2:689-692.
21. Boehm T, Folkman J, Browder T, O'Reilly MS. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature 1997; 390:404-407.
22. Teicher BA, Emi Y, Kakeji Y, Northey D. TNP-470/minocycline/cytotoxic therapy: A systems approach to cancer therapy. Eur J Cancer 1996; 32A:2461-2466.
23. Mauceri HJ, Hanna NN, Beckett MA, Gorski DH, Staba M-J, Stellato KA, Bigelow K, Heimann R, Gately S, Dhanabal M, Soff GA, Sukhatme VP, Kufe DW, Weichselbaum RR. Combined effects of angiostatin and ionizing radiation in antitumour therapy. Nature 1998; 394:287-291.
24. Huang X, Molema G, King S, Watkins L, Edgington TS, Thorpe PE. Tumor infarction in mice by antibody-directed targeting of tissue factor to tumor vasculature. Science 1997; 275:547-550.
25. Pasqualini R, Koivunen E, Rouslahti E. αv integrins as receptors for tumor targeting by circulating ligands. Nature Biotech 1997; 15:542-546.
26. Ran S, Gao B, Duffy S, Watkins L, Rote N, Thorp PE. Infarction of solid Hodgkin's tumors in mice by antibody-directed targeting of tissue factor to tumor vasculature. Cancer Res 1998; 58:4646-4653.
27. Blijham GH. Prevention and treatment of organ toxicity during high-dose chemotherapy: an overview. Anticancer Drugs 1993; 4:527-533.
28. Gasparini G, Presta M. Clinical studies with angiogenesis inhibitors: Biological rationale and challenges for their evaluation. Ann Oncol 1996; 7:441-444.
29. Holmgren L, O'Reilly MS, Folkman J. Dormancy of micrometastases: Balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nature Med 1995; 1:149-153.
30. Klauber N, Rohan RM, Flynn E, D'Amato RJ. Critical components of the female reproductive pathway are suppressed by the angiogenesis inhibitor AGM-1470. Nature Med 1997; 3:443-446.
31. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nature Med 1995; 1:27-31.
32. Jain RK. Barriers to drug delivery in solid tumors. Sci Am 1994; 271:58-65.
33. Denekamp J. Vascular attack as a therapeutic strategy for cancer. Cancer Metastasis Rev 1990; 9:267-282.
34. Dirix LY, Vermulen PB, Pawinski A, Prové A, Benoy I, De Pooter C, Martin M, Van Oosterom AT. Elevated levels of the angiogenic cytokines basic fibroblast growth factor and vascular endothelial growth factor in sera of cancer patients. Br J Cancer 1997; 76:238-243.
35. Linder C, Linder S, Munck-Wikland E, Strander H. Independent expression of serum vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) in patients with carcinoma and sarcoma. Anticancer Res 1998; 18:2063-2068.
36. Nguyen M, Watanabe H, Budson AE, Richie JP, Hayes DF, Folkman J. Elevated levels of an angiogenic peptide, basic fibroblast growth factor, in the urine of patients with a wide spectrum of cancers. J Natl Cancer Inst 1994; 86:356-361.
37. Lin RY, Argenta PA, Sullivan KM, Adzick NS. Diagnostic and prognostic role of basic fibroblast growth factor in Wilms' tumor patients. Clin Cancer Res 1995; 1:327-331.
38. Perez-Atayde AR, Sallan SE, Tedrow U, Connors S, Allred E, Folkman J. Spectrum of tumor angiogenesis in the bone marrow of children with acute lymphoblastic leukemia. Am J Pathol 1997; 150:815-821.
39. Vermeulen PB, Gasparini G, Fox SB, Toi M, Martin L, McCulloch P, Pezzella F, Viale G, Weidner N, Harris AL, Dirix LY. Quantification of angiogenesis in solid human tumours: an international consensus on the methodology and criteria of evaluation. Eur J Cancer 1996; 32A:2474-2484.
40. Meitar D, Crawford SE, Rademaker AW, Cohn SL. Tumor angiogenesis correlates with metastatic disease, N-myc amplification, and poor outcome in human neuroblastoma. J Clin Oncol 1996; 14:405-414.
41. Wassberg E, Påhlman S, Westlin J-E, Christofferson R. The angiogenesis inhibitor TNP-470 reduces the growth rate of human neuroblastoma in nude rats. Pediatr Res 1997; 41:327-333.
42. Biedler JL, Helson L, Spengler BA. Morphology and growth, tumorigenicity, and cytogenetics of human neuroblastoma cells in continuous culture. Cancer Res 1973; 33:2643-2652.
43. Biedler JL, Roffler-Tarlov S, Schaschner M, Freedman LS. Multiple neurotransmitter synthesis by human neuroblastoma cell lines and clones. Cancer Res 1978; 38:3751-3757.
44. Wassberg E, Stridsberg M, Christofferson R. Plasma levels of chromogranin A are directly proportional to tumour burden in neuroblastoma. J Endocrinol 1996; 151:225-230.
45. Wassberg E, Hedborg F, Sköldenberg E, Stridsberg M, Christofferson R. Inhibition of angiogenesis induces chromaffin differentiation and apoptosis in neuroblastoma. Am J Pathol 1999; 154:395-403.
46. Wassberg E, Sundelöf J, Pribluda VS, Green SJ, Hedborg F, Christofferson R. The antiangiogenic and chemotherapeutic natural steroid 2-methoxyestradiol and its derivative 2-propynylestradiol are potent suppressors of neuroblastoma growth when administered orally. Submitted.
47. Nilsson S, Pählman S, Arnberg H, Letocha H, Westlin J-E. Characterization and uptake of radiolabelled meta-iodobenzylguanidine (MIBG) in a human neuroblastoma heterotransplant model in athymic rats. Acta Oncol 1993; 32:887-891.
48. Påhlman S, Hoehner JC, Nånberg E, Hedborg F, Fagerström S, Gestblom C, Johansson I, Larsson U, Lavenius E, Örtoft E, Söderholm H. Differentiation and survival influences of growth factors in human neuroblastoma. Eur J Cancer 1995; 31A:453-458.
49. Festing MFW. Characteristics of nude rats. In Proceedings of the third international workshop on nude mice. Gustav Fisher, New York, 1982, pp 41-49.
50. Hougen HP. The athymic nude rat. APMIS suppl 21 1991; 99:7-39
51. Fogh J, Fogh JM, Orfeo T. One hundred and twenty-seven cultured human tumor cell lines producing tumors in nude mice. J Natl Cancer Inst 1977; 59:221-226.
52. Phillips RA, Jewett MAS, Gallie BL. Growth of human tumors in immune-deficient seid mice and nude mice. Curr Top Microbiol Immunol 1989; 152:259-263.
53. Tomayko MM, Reynolds CP. Determination of subcutaneous tumor size in athymic (nude) mice. Cancer Chemother Pharmacol 1989; 24:148-154.
54. Elias H, Hyde DM. Elementary stereology. Am J Anat 1980; 159:411-446.
55. Hayes CE, Goldstein IJ. An alpha-D-galactosyl-binding lectin from Bandeiraea simplicifolia seeds. Isolation by affinity chromatography and characterization. J Biol Chem 1974; 249:1904-1914.
56. Weibel ER. Stereological methods. London, Academic Press Inc. 1979.
57. Gundersen HJG, Bendtsen TF, Korbo L, Marcussen N, Møller A, Nielsen K, Nyengaard JR, Pakkenberg B, Sørensen FB, Vesterby A, West MJ. Some new. simple and efficient stereological methods and their use in pathological research and diagnosis. APMIS 1988; 96:379-394.
58. Woods WG, Tuchman M, Robison LL, Bernstein M, Leclerc JM, Brisson LC, Brossard J, Hill G, Shuster J, Luepker R, Byrne T, Weitzman S, Bunin G, Lemieux B. A population-based study of the usefulness of screening for neuroblastoma. Lancet 1996; 348:1682-1687.
59. Joshi VV, Cantor AB, Altshuler G, Larkin EW, Neill JSA, Shuster JJ, Holbrook CT, Hayes FA, Nitschke R, Duncan MH, Shochat SJ, Talbert J, Smith EI, Castleberry RP. Age-linked prognostic categorization based on a new histologic grading system of neuroblastomas. Cancer 1992; 69:2197-2211.
60. Hoehner JC, Hedborg F, Wiklund HJ, Olsen L, Påhlman S. Cellular death in neuroblastoma: in situ correlation of apoptosis and bcl-2 expression. Int J Cancer 1995; 62:19-24.
61. Hoehner JC, Gestblom C, Hedborg F, Sandstedt B, Olsen L, Påhlman S. A developmental model of neuroblastoma: differentiating stroma-poor tumor's progress along an extra-adrenal chromaffin lineage. Lab Invest 1996; 75:659-675.
62. Hedborg F, Ohlsson R, Sandstedt B, Grimelius L, Hoehner J, Påhlman S. IGF2 expression is a marker for paraganglionic/SIF cell differentiation in neuroblastoma. Am J Pathol 1995; 146:833-847.
63. Gestblom C, Hoehner JC, Hedborg F, Sandstedt B, Påhlman S. In vivo spontaneous neuronal to neuroendocrine lineage conversion in a subset of neuroblastomas. Am J Pathol 1997; 150:107-117.
64. Hendy GN, Bevan S, Mattei M-G, Mouland AJ. Review: Chromogranin A. Clin Invest Med 1995; 18:47-65.
65. Ingber D, Fujita T, Kishimoto S, Sudo K, Kanamaru T, Brem H, Folkman J. Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumor growth. Nature 1990; 348:555-557
66. Castronovo V, Belotti D. TNP-470 (AGM-1470): Mechanism of action and early clinical development. Eur J Cancer 1996; 32A:2520-2527.
67. Nagabuchi E, VanderKolk WE, Une Y, Ziegler MM. TNP-470 antiangiogenic therapy for advanced murine neuroblastoma. J Pediatr Surg 1997; 32:287-293.
68. Fotsis Fotsis T, Zhang Y, Pepper MS, Adlercreutz H, Montesano R, Nawroth PP, Schweigerer L The endogenous oestrogen metabolite 2-methoxyoestradiol inhibits angiogenesis and suppresses tumour growth. Nature 1994; 368:237-239.
69. Klauber N, Parengi S, Flynn E, Hamel E, D'Amato R. Inhibition of angiogenesis and breast cancer in mice by the microtubule inhibitors 2-methoxyestradiol and taxol. Cancer Res 1997; 57:81-86.
70. Crum R, Szabo S, Folkman J. A new class of steroids inhibits angiogenesis in the presence of heparin or a heparin fragment. Science 1985; 230:1375-1378.
71. Pribluda VS, Green SJ. 2-methoxyestradiol: a novel endogenous chemotherapeutic and antiangiogenic. In Fan T-P, Auerbach R (ed) The New Angiotherapy. In press.
72. Zukowska-Grojec Z, Karwatowska-Prokopczuk E, Rose W, Rone J, Movafagh S, Ji H, Yeh Y, Chen WT, Kleinmann HK, Grouzmann E, Grant DS. Neuropeptide Y: a novel angiogenic factor from the sympathetic nerves and endothelium. Circ Res 1998; 83:187-195.
73. Wojtowicz-Praga SM, Dickson RB, Hawkins MJ. Matrix metalloproteinase inhibitors. Invest New Drugs 1997; 15:61-75.
74. Berlin J, Tutsch KD, Hutson P, Cleary J, Rago RP, Arzoomanian RZ, Alberti D, Feierabend C, Wilding G. Phase I clinical and pharmacokinetic study of oral carboxyamidotriazole, a signal transduction inhibitor. J Clin Oncol 1997; 15:781-789.
75. DeVore RF, Hellerqvist CG, Wakefield GB, Wamil BD, Thurman GB, Minton PA, Sundell HW, Van H-P, Carter CE, Wang Y-F, York GE, Zhang M-H, Johnson DH. A phase I study of the antineovascularization drug CM101. Clin Cancer Res 1997; 3:365-372.
76. Chang E, Boyd A, Nelson CC, Crowley D, Law T, Keough KM, Folkman J, Ezekowitz RAB, Castle VP. Successful treatment of infantile hemangiomas with interferon-α-2b. J Pediatr Hematol Oncol 1997; 19:237-244.
77. Voest EE, Kenyon B, O'Reilly MS, Truitt G, D'Amato RJ, Folkman J. Inhibition of angiogenesis in vivo by interleukin 12. J Natl Cancer Inst 1995; 87:581-586.
78. Vukanovic J, Passaniti A, Hirata T, Traystmann RJ, Hartley-Asp B, Isaacs JT. Antiangiogenic effect of the quinoline-3-carboxamide linomide. Cancer Res 1993; 53:1833-1837.
79. Kahn J, Ruiz R, Kershmann R, Berger T, Ma R, Coleman R, Alford B, Kaplan L. A phase I/II study of recombinant platelet factor 4 (rPF4) in patients with AIDS related Kaposi's sarcoma (KS). Proc Am Soc Clin Oncol 1993; 12:50.
80. Strawn LM, McMahon G, App H, Schreck R, Kuchler WR, Longhi MP, Hui TH, Tang C, Levitzki A, Gazit A, Chen I, Keri G, Orfi L, Risau W, Flamme I, Ullrich A, Hirth KP, Shawver LK Flk-1 as a target for tumor growth inhibition. Cancer Res 1996; 56:3540-3545.
81. Mirza MR, Jakobsen E, Pfeiffer P, Lindeberg-Clasen B, Bergh J, Rose C. Suramin in non-small cell lung cancer and advanced breast cancer. Two parallel phase II studies. Acta Oncol 1997; 36:171-174.
82. Eckhardt SG, Burris HA, Eckardt JR, Weiss G, Rodriguez G, Rothenberg M, Rinaldi D, Barrington R, Kuhn JK, Masuo K, Sudo K, Atsumi R, Oguma T, Higashi L, Fields S, Smetzer L, Von Hoff DD. A phase I clinical and pharmacokinetic study of the angiogenesis inhibitor, tecogalan sodium. Ann Oncol 1996; 7:491-496.
83. D'Amato RJ, Loughnan MS, Flynn E, Folkman J. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA 1994; 91:4082-4085.
84. Figg WD, Pluda JM, Lush RM, Saville MW, Wyvill K, Reed E, Yarchoan R. The pharmacokinetics of TNP-470, a new angiogenesis inhibitor. Pharmacotherapy 1997; 17:91-97.
85. Christofferson R. Angiogeneshämmare vid avancerad cancer - många påbörjade kliniska prövningar visar lovande resultat. (Angiogenesis inhibitors in advanced cancer: many clinical trials are yielding promising results.) Läkartidningen 1998; 95:2349-2354. In Swedish.
86. Davis S, Aldrich TH, Jones PF, Acheson A, Compton DL, Jain V, Ryan TE, Bruno J, Radziejewski C, Maisonpierre PC, Yancopoulos GD. Isolation of angiopoietin-1, a ligand for the TIE2 receptor, by secretion-trap expression cloning. Cell 1996; 87:1161-1169.
87. Sierra-Honigmann MR, Nath AK, Murakami C, Garcia-Cardena G, Papapetropoulos A, Sessa WC, Madge LA, Schechner JS, Schwabb MB, Polverini PJ, Flores-Riveros JR. Biological action of leptin as an angiogenic factor. Science 1998; 281:1683-1686.
88. Bouloumie A, Drexler HC, Lafontan M, Busse R. Leptin, the product of Ob gene, promotes angiogenesis. Circ Res 1998; 83:1059-1066.